ReviewExpert review of neurotherapeutics2011
The corticobasal syndrome-Alzheimer's disease conundrum.
Review in Expert review of neurotherapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 76 citations in OpenAlex.
- Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The Adult Neurogenesis Theory of Alzheimer's Disease Predicts Where Tauopathy Develops in the Brain.International journal of molecular sciences · 2026Review
- Atypical Alzheimer disease: a multi-axis framework toward defining heterogeneity.Nature reviews. Neurology · 2026Review
- Atypical Imaging Findings in Corticobasal Syndrome: A Case Report.Journal of movement disorders · 2025Article
- Healthcare Complexities in Neurodegenerative Proteinopathies: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- A Case of Combined Corticobasal Degeneration and Alzheimer's Disease Pathology: Clinical Presentation, and Diagnosis.Dementia and neurocognitive disorders · 2025Article
- Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.Annals of neurology · 2024Article
- Diagnosis and Management of Progressive Corticobasal Syndrome.Current treatment options in neurology · 2024Article
- Neuropathological hints from CSF and serum biomarkers in corticobasal syndrome (CBS): a systematic review.Neurological research and practice · 2024Review
- Boundary-based registration improves sensitivity for detecting hypoperfusion in sporadic frontotemporal lobar degeneration.Frontiers in neurology · 2024Article
- Virtual brain simulations reveal network-specific parameters in neurodegenerative dementias.Frontiers in aging neuroscience · 2023Article
- TREM2 risk variants are associated with atypical Alzheimer's disease.Acta neuropathologica · 2022Article
- The Significance of Asymmetry in the Assessment of Brain Perfusion in Atypical Tauopathic Parkinsonian Syndromes.Diagnostics (Basel, Switzerland) · 2022Article
- Differential Diagnosis of Rare Subtypes of Progressive Supranuclear Palsy and PSP-Like Syndromes-Infrequent Manifestations of the Most Common Form of Atypical Parkinsonism.Frontiers in aging neuroscience · 2022Review
- Clinical Spectrum of Tauopathies.Frontiers in neurology · 2022Review
- Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD.Journal of neuropathology and experimental neurology · 2020Article
- Longitudinal Amyloid-β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration.Journal of Alzheimer's disease : JAD · 2020Article
- Astrocytic Tau Deposition Is Frequent in Typical and Atypical Alzheimer Disease Presentations.Journal of neuropathology and experimental neurology · 2019Article
- Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2019Article
- Diagnosing Corticobasal Syndrome Based on the Presence of Visual Hallucinations and Imaging with Amyloid Positron Emission Tomography.Internal medicine (Tokyo, Japan) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Corticobasal syndrome (CBS), once thought to be pathognomonic for corticobasal degeneration pathology, is increasingly reported with various underlying pathologies. Alzheimer's disease is one such pathology, also once believed to be unique for its clinical syndrome of dementia of the Alzheimer's type. CBS is believed to result from topography of asymmetric parietofrontal cortical lesion involvement, rather than lesion subtype. However, this topographical pattern is strikingly different to that typically associated with AD for unclear reasons. This article will focus on CBS with underlying AD pathology (CBS-AD), and will review associated clinical, imaging and demographic factors. Predicting AD pathology is of marked interest as disease-modifying therapies loom on the horizon, with biomarkers and imaging research underway. By reviewing the literature for CBS-AD case reports and series and contrasting them with CBS with underlying corticobasal degeneration pathology cases, the article aims to examine factors that may predict AD pathology. How AD pathology may produce this clinical phenotype, rather than the prototype dementia of the Alzheimer's type, will also be reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.